Rikoon Group LLC decreased its holdings in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 4.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 6,088 shares of the company’s stock after selling 266 shares during the period. Rikoon Group LLC’s holdings in Crispr Therapeutics were worth $250,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of CRSP. SG Americas Securities LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter worth approximately $758,000. First Trust Advisors LP purchased a new stake in Crispr Therapeutics in the 3rd quarter worth $987,000. Traynor Capital Management Inc. grew its holdings in shares of Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after buying an additional 375 shares in the last quarter. California Public Employees Retirement System grew its holdings in shares of Crispr Therapeutics by 23.7% in the third quarter. California Public Employees Retirement System now owns 17,200 shares of the company’s stock valued at $705,000 after purchasing an additional 3,300 shares during the period. Finally, Commonwealth Equity Services LLC lifted its position in Crispr Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after buying an additional 386 shares during the last quarter. 49.81% of the stock is currently owned by institutional investors and hedge funds.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by company insiders.
CRSP has been the subject of a number of recent analyst reports. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $69.54.
Shares of NASDAQ:CRSP opened at $71.65 on Monday. The business has a 50 day moving average price of $49.98 and a 200 day moving average price of $46.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics AG has a twelve month low of $22.22 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Research analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.